榴莲视频

-- News, features, and commentary about cancer-related issues

Debate highlights pros and cons of the new recommendation

Osimertinib plus ramucirumab in first line shows 9-month PFS advantage over EGFR inhibition alone

Study raises questions about how to assess patient risk, experts say

News, features, and commentary about cancer-related issues

Latest negative results emphasize "critical" aspect of immunotherapy timing

EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy

Actual rates for 2021 lagged behind projections

News, features, and commentary about cancer-related issues

Cancer patients with cachexia added needed pounds with GDF-15 antibody

News, features, and commentary about cancer-related issues

Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan

However, plinabulin plus docetaxel still "not ready for prime time," expert says

Absolute improvement of almost 30%, doubling of duration of response with savolitinib